• Johnson & Johnson Innovation – JJDC, Inc., RTW Investments, LP and Wille AG participated within the funding spherical

  • Funding will assist advance lead product candidate BRIMOCHOL in pivotal registration research

Visus Therapeutics Inc. (the “Firm”), a clinical-stage pharmaceutical firm looking for to develop the world’s first presbyopia correcting eye drops that may final not less than eight hours, at this time introduced the closing of a Collection A of 36 hundreds of thousands of {dollars}. Financing of most well-liked shares. Johnson & Johnson innovation JJDC, Inc. (JJDC), RTW Investments, LP and Wille AG participated within the spherical, with extra participation from current shareholders of the corporate. Proceeds from the Collection A funding will probably be used to advance the scientific improvement program of the Firm’s core asset, BRIMOCHOL ™, an investigational drug designed to be a once-daily eye drop to appropriate related close to imaginative and prescient loss. to presbyopia.

“We’re dedicated to delivering on the promise of bringing a transformative resolution to at this time’s presbyopia therapy panorama,” stated Ben Bergo, Co-Founder and CEO of Visus. “With our Collection A funding and with the help of our seasoned healthcare traders, Visus is effectively positioned to quickly advance our scientific improvement program for BRIMOCHOL.”

“Visus’s skilled administration crew has a profitable monitor file within the improvement of eye care medication. This offers us nice confidence that the Visus crew can develop life-changing therapies for individuals with presbyopia, ”stated Tony Nguyen, Managing Director at RTW Investments, LP, who has been appointed to the board of administration of Visus. “Visus’ extremely differentiated therapeutic method to the therapy of presbyopia has the potential to be a big step ahead on this rising class. We sit up for supporting the Visus crew as they advance this system of scientific improvement of BRIMOCHOL. “

About presbyopia

Presbyopia is the lack of close to imaginative and prescient related to getting old, which makes it tough to carry out duties equivalent to studying small print. It normally begins when adults are of their 40s and turns into nearly common by age 50.1 Presbyopia impacts billions of individuals worldwide and an estimated 123 million adults are affected in the USA alone.2 Studying glasses are the commonest resolution for close to imaginative and prescient correction. Nonetheless, many individuals typically discover glasses impractical and / or desire to not put on them for beauty causes. At present, there is no such thing as a FDA permitted drug for presbyopia.

About Visus Therapeutics

Visus Therapeutics is a scientific stage firm looking for to develop the world’s first presbyopia correcting eye drops with the potential to final not less than eight hours. With workplaces in Seattle and Orange County, California, its lead scientific candidate is BRIMOCHOL, a watch drop designed to appropriate the lack of close to imaginative and prescient related to presbyopia. On the similar time, Visus Therapeutics is concentrated on advancing its portfolio of early stage ophthalmic product candidates. For extra data go to: www.visustx.com and observe us on Twitter (@VisusTx) and on LinkedIn.

1 US census knowledge, www.census.gov, accessed September 7, 2019.
2 Market Scope, World Presbyopia-Correcting Surgical procedure Market Report, April 2012.

See the supply model on businesswire.com: https://www.businesswire.com/information/residence/20210309005270/en/

Contacts

Enterprise & Biotech Press:
Sierra smith
[email protected]
(408) 540-4296

Skilled eye care press:
Michele grey
[email protected]
(917) 449-9250





Supply hyperlink